{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:34:25Z","timestamp":1791347665020,"version":"4.3.1"},"reference-count":132,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>The treatment of Acinetobacter baumannii infections remains a challenge for physicians worldwide in the 21st century. The bacterium possesses a multitude of mechanisms to escape the human immune system. The consequences of A. baumannii infections on morbidity and mortality, as well on financial resources, remain dire. Furthermore, A. baumannii superinfections have also occurred during the COVID-19 pandemic. While prevention is important, the antibiotic armamentarium remains the most essential factor for the treatment of these infections. The main problem is the notorious resistance profile (including resistance to carbapenems and colistin) that this bacterium exhibits. While newer beta lactam\/beta-lactamase inhibitors have entered clinical practice, with excellent results against various infections due to Enterobacteriaceae, their contribution against A. baumannii infections is almost absent. Hence, we have to resort to at least one of the following, sulbactam, polymyxins E or B, tigecycline or aminoglycosides, against multidrug-resistant (MDR) and extensively drug-resistant (XDR) A. baumannii infections. Furthermore, the notable addition of cefiderocol in the fight against A. baumannii infections represents a useful addition. We present herein the existing information from the last decade regarding therapeutic advances against MDR\/XDR A. baumannii infections.<\/jats:p>","DOI":"10.3390\/antibiotics13030261","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T12:02:39Z","timestamp":1710504159000},"page":"261","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections"],"prefix":"10.3390","volume":"13","author":[{"given":"Petros","family":"Rafailidis","sequence":"first","affiliation":[{"name":"Second University Department of Internal Medicine, University General Hospital of Alexandroupolis, 681 00 Alexandroupolis, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Periklis","family":"Panagopoulos","sequence":"additional","affiliation":[{"name":"Second University Department of Internal Medicine, University General Hospital of Alexandroupolis, 681 00 Alexandroupolis, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Koutserimpas","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics and Traumatology, \u201c251\u201d Hellenic Air Force General Hospital of Athens, 115 25 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Samonis","sequence":"additional","affiliation":[{"name":"Department of Oncology, Metropolitan Hospital, 185 47 Athens, Greece"},{"name":"Department of Medicine, University of Crete, 715 00 Heraklion, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Pogue, J.M., Zhou, Y., Kanakamedala, H., and Cai, B. (2022). Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019. BMC Infect Dis., 22.","DOI":"10.1186\/s12879-021-07024-4"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1128\/CMR.00058-07","article-title":"Acinetobacter baumannii: Emergence of a successful pathogen","volume":"21","author":"Peleg","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Iovleva, A., Mustapha, M.M., Griffith, M.P., Komarow, L., Luterbach, C., Evans, D.R., Cober, E., Richter, S.S., Rydell, K., and Arias, C.A. (2022). Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance. mBio, 13.","DOI":"10.1128\/mbio.02759-21"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1093\/cid\/ciy671","article-title":"A Case-Control Study: Clinical Characteristics of Nosocomial Bloodstream Infections Versus Non-Bloodstream Infections of Acinetobacter spp.","volume":"67","author":"Xu","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jhm.2477","article-title":"Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study","volume":"11","author":"Zilberberg","year":"2016","journal-title":"J. Hosp. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_7","first-page":"1803","article-title":"Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jinf.2019.09.012","article-title":"The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: A systematic review and meta-analysis","volume":"79","author":"Liew","year":"2019","journal-title":"J. Infect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America Guidance on the Treatment of AmpC \u03b2-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0732-8893(85)80005-5","article-title":"In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies","volume":"3","author":"Jones","year":"1985","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/BF01968142","article-title":"In vitro activity of cefoperazone-sulbactam combinations against cefoperazone-resistant clinical bacterial isolates","volume":"8","author":"Eliopoulos","year":"1989","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/jac\/42.6.793","article-title":"Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii","volume":"42","author":"Corbella","year":"1998","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/clinids\/22.6.1026","article-title":"Bacteremia due to Acinetobacter baumannii: Epidemiology, clinical findings, and prognostic features","volume":"22","author":"Cisneros","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1592\/phco.21.2.142.34114","article-title":"Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam","volume":"21","author":"Jellison","year":"2001","journal-title":"Pharmacotherapy"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1086\/340055","article-title":"Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia","volume":"34","author":"Wood","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0924-8579(02)00276-5","article-title":"Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin\/sulbactam","volume":"21","author":"Levin","year":"2003","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0195-6701(03)00046-X","article-title":"Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: Risk factors and outcome with ampicillin-sulbactam treatment","volume":"54","author":"Smolyakov","year":"2003","journal-title":"J. Hosp. Infect."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/jac\/dkn128","article-title":"Ampicillin\/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp.","volume":"61","author":"Oliveira","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jinf.2008.04.002","article-title":"Efficacy and safety of high-dose ampicillin\/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"56","author":"Betrosian","year":"2008","journal-title":"J. Infect."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3109\/00365548.2014.995129","article-title":"Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex","volume":"47","author":"Lin","year":"2015","journal-title":"Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1097\/MJT.0b013e3182a32df3","article-title":"Treatment of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia: Retrospective Comparison between Intravenous Colistin and Intravenous Ampicillin-Sulbactam","volume":"23","author":"Zalts","year":"2016","journal-title":"Am. J. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jmii.2015.06.009","article-title":"Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests","volume":"49","author":"Jean","year":"2016","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"588","DOI":"10.5414\/CP202557","article-title":"Comparison of the efficacies of three empirically-selected antibiotics for treating Acinetobacter baumannii pulmonary infection: Experience from a teaching hospital in China","volume":"55","author":"Li","year":"2017","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_25","first-page":"161","article-title":"Treatment efficacy of tigecycline in comparison to cefoperazone\/sulbactam alone or in combination therapy for carbapenem-resistant Acinetobacter baumannii infections","volume":"33","author":"Li","year":"2020","journal-title":"Pak. J. Pharm. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5414\/CP203102","article-title":"Comparison of the treatment efficacy between tigecycline plus high-dose cefoperazone-sulbactam and tigecycline monotherapy against ventilator-associated pneumonia caused by extensively drug-resistant Acinetobacter baumannii","volume":"56","author":"Qin","year":"2018","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.2147\/IDR.S225518","article-title":"Clinical Outcomes of Colistin in Combination with Either 6-G Sulbactam or Carbapenems for the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Pneumonia with High MIC to Sulbactam, A Prospective Cohort Study","volume":"12","author":"Ungthammakhun","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2217\/cer-2018-0037","article-title":"Meropenem\/colistin versus meropenem\/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia","volume":"7","author":"Khalili","year":"2018","journal-title":"J. Comp. Eff. Res."},{"key":"ref_29","first-page":"206","article-title":"Interim Study: Comparison of Safety and Efficacy of Levofloxacin Plus Colistin Regimen with Levofloxacin Plus High Dose Ampicillin\/Sulbactam Infusion In Treatment of Ventilator-Associated Pneumonia Due To Multi Drug Resistant Acinetobacter","volume":"17","author":"Mosaed","year":"2018","journal-title":"Iran. J. Pharm. Res."},{"key":"ref_30","first-page":"269","article-title":"Comparison of Intravenous Ampicillin-sulbactam Plus Nebulized Colistin with Intravenous Colistin Plus Nebulized Colistin in Treatment of Ventilator Associated Pneumonia Caused by Multi Drug Resistant Acinetobacter baumannii: Randomized Open Label Trial","volume":"18","author":"Pourheidar","year":"2019","journal-title":"Iran. J. Pharm. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: A multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ungthammakhun, C., Vasikasin, V., and Changpradub, D. (2022). A Randomized Controlled Trial of Colistin Combined with Sulbactam: 9 g per Day versus 12 g per Day in the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Pneumonia: An Interim Analysis. Antibiotics, 11.","DOI":"10.3390\/antibiotics11081112"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): A randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.ajic.2019.01.010","article-title":"Attributable mortality from extensively drug-resistant gram-negative infections using propensity-matched tracer antibiotic algorithms","volume":"47","author":"Kadri","year":"2019","journal-title":"Am. J. Infect. Control"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"dlab174","DOI":"10.1093\/jacamr\/dlab174","article-title":"Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: A multicentre cohort study","volume":"3","author":"Pascale","year":"2021","journal-title":"JAC-Antimicrob. Resist."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e0214221","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol-Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Mazzitelli, M., Gregori, D., Sasset, L., Trevenzoli, M., Scaglione, V., Lo Menzo, S., Marinello, S., Mengato, D., Venturini, F., and Tiberio, I. (2023). Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Acinetobacter baumannii Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic. Microorganisms, 11.","DOI":"10.3390\/microorganisms11040984"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s40121-023-00854-6","article-title":"Cefiderocol Versus Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii Complex Bloodstream Infections: A Retrospective, Propensity-Score Adjusted, Monocentric Cohort Study","volume":"12","author":"Bavaro","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"dlad085","DOI":"10.1093\/jacamr\/dlad085","article-title":"Cefiderocol-containing regimens for the treatment of carbapenem-resistant A. baumannii ventilator-associated pneumonia: A propensity-weighted cohort study","volume":"5","author":"Rando","year":"2023","journal-title":"JAC-Antimicrob. Resist."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Dalfino, L., Stufano, M., Bavaro, D.F., Diella, L., Belati, A., Stolfa, S., Romanelli, F., Ronga, L., Di Mussi, R., and Murgolo, F. (2023). Effectiveness of First-Line Therapy with Old and Novel Antibiotics in Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant Acinetobacter baumannii: A Real Life, Prospective, Observational, Single-Center Study. Antibiotics, 12.","DOI":"10.3390\/antibiotics12061048"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"106825","DOI":"10.1016\/j.ijantimicag.2023.106825","article-title":"Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19","volume":"62","author":"Russo","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Mezcord, V., Escalante, J., Nishimura, B., Traglia, G.M., Sharma, R., Vall\u00e9, Q., Tuttobene, M.R., Subils, T., Marin, I., and Pasteran, F. (2023). Induced Heteroresistance in Carbapenem-Resistant Acinetobacter baumannii (CRAB) via Exposure to Human Pleural Fluid (HPF) and Its Impact on Cefiderocol Susceptibility. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202306.0950.v1"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1093\/jac\/dkz123","article-title":"Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects","volume":"74","author":"Katsube","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1089\/mdr.2022.0279","article-title":"In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined \u03b2-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014\u20132019","volume":"29","author":"Wise","year":"2023","journal-title":"Microb. Drug Resist."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1093\/jac\/dkad200","article-title":"In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014\u20132019)","volume":"78","author":"Takemura","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Shortridge, D., Streit, J.M., Mendes, R., and Castanheira, M. (2022). In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program. Microbiol. Spectr., 10.","DOI":"10.1128\/spectrum.02712-21"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jgar.2022.11.013","article-title":"In vitro activity of cefiderocol against clinically important carbapenem non-susceptible Gram-negative bacteria from Saudi Arabia","volume":"32","author":"Alzayer","year":"2023","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10096-023-04616-7","article-title":"In vitro activities of omadacycline, eravacycline, cefiderocol, apramycin, and comparator antibiotics against Acinetobacter baumannii causing bloodstream infections in Greece, 2020\u20132021: A multicenter study","volume":"42","author":"Galani","year":"2023","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Lupia, T., Corcione, S., Shbaklo, N., Montrucchio, G., De Benedetto, I., Fornari, V., Bosio, R., Rizzello, B., Mornese Pinna, S., and Brazzi, L. (2022). Meropenem\/Vaborbactam and Cefiderocol as Combination or Monotherapy to Treat Multi-Drug Resistant Gram-Negative Infections: A Regional Cross-Sectional Survey from Piedmont Infectious Disease Unit Network (PIDUN). J. Funct. Biomater., 13.","DOI":"10.3390\/jfb13040174"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1186\/s13063-021-05870-w","article-title":"Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): Study protocol for an open-label, randomised controlled trial","volume":"22","author":"Wright","year":"2021","journal-title":"Trials"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2020.08.021","article-title":"Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis","volume":"24","author":"Liu","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1086\/514732","article-title":"Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii","volume":"28","author":"Levin","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/cc2358","article-title":"Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients","volume":"7","author":"Markou","year":"2003","journal-title":"Crit. Care"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/374337","article-title":"Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: A comparison with imipenem-susceptible VAP","volume":"36","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s00134-005-2691-4","article-title":"Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: A prospective cohort study","volume":"31","author":"Reina","year":"2005","journal-title":"Intensive Care Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/j.1469-0691.2006.01559.x","article-title":"Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections","volume":"12","author":"Falagas","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1007\/s00134-007-0675-2","article-title":"Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: A matched case-control study","volume":"33","author":"Kallel","year":"2007","journal-title":"Intensive Care Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ijid.2006.09.011","article-title":"Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand","volume":"11","author":"Koomanachai","year":"2007","journal-title":"Int. J. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijantimicag.2009.10.005","article-title":"Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: A retrospective cohort study of 258 patients","volume":"35","author":"Falagas","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: A multicenter, randomized clinical trial","volume":"57","author":"Signoriello","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s10096-014-2070-6","article-title":"Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections","volume":"33","author":"Batirel","year":"2014","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s15010-013-0495-y","article-title":"Comparison of colistin and colistin\/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"42","author":"Kalin","year":"2014","journal-title":"Infection"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1093\/jac\/dku233","article-title":"Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: Analysis of a multicentre prospective cohort","volume":"69","author":"Cisneros","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/CCM.0000000000000933","article-title":"Excess Mortality Associated with Colistin-Tigecycline Compared with Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study","volume":"43","author":"Cheng","year":"2015","journal-title":"Crit. Care Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3855\/jidc.6195","article-title":"Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia","volume":"9","author":"Yilmaz","year":"2015","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4103\/0253-7613.150383","article-title":"Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: A multicenter retrospective analysis","volume":"47","author":"Balkan","year":"2015","journal-title":"Indian. J. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cmi.2017.09.016","article-title":"The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii","volume":"24","author":"Amat","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/ijccm.IJCCM_302_17","article-title":"Colistin versus Colistin Combined with Ampicillin-Sulbactam for Multiresistant Acinetobacter baumannii Ventilator-associated Pneumonia Treatment: An Open-label Prospective Study","volume":"22","author":"Makris","year":"2018","journal-title":"Indian J. Crit. Care Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1177\/0300060519879336","article-title":"Survival of carbapenem-resistant Acinetobacter baumannii bacteremia: Colistin monotherapy versus colistin plus meropenem","volume":"47","author":"Park","year":"2019","journal-title":"J. Int. Med. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1038\/s41598-022-11061-7","article-title":"Clinical outcome of nosocomial pneumonia caused by Carbapenem-resistant gram-negative bacteria in critically ill patients: A multicenter retrospective observational study","volume":"12","author":"Chen","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"EVIDoa2200131","DOI":"10.1056\/EVIDoa2200131","article-title":"Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms","volume":"2","author":"Kaye","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: An open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2017.05.016","article-title":"Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: A systematic review and meta-analysis","volume":"51","author":"Vardakas","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"154315","DOI":"10.1016\/j.jcrc.2023.154315","article-title":"Nebulized colistin as the adjunctive treatment for ventilator-associated pneumonia: A systematic review and meta-analysis","volume":"77","author":"Zhang","year":"2023","journal-title":"J. Crit. Care"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.3171\/2017.8.FOCUS17443","article-title":"The 21st-century challenge to neurocritical care: The rise of the superbug Acinetobacter baumannii. A meta-analysis of the role of intrathecal or intraventricular antimicrobial therapy in reduction of mortality","volume":"43","author":"Mohammed","year":"2017","journal-title":"Neurosurg. Focus."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1086\/674387","article-title":"A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia","volume":"35","author":"Ng","year":"2014","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1128\/AAC.02476-13","article-title":"In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy","volume":"58","author":"Phe","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00365548.2013.844350","article-title":"Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy","volume":"46","author":"Crusio","year":"2014","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1128\/AAC.00844-15","article-title":"Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods","volume":"59","author":"Nelson","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/jac\/dku561","article-title":"Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: A multicentre prospective cohort study","volume":"70","author":"Rigatto","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.1128\/AAC.00494-15","article-title":"Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections","volume":"59","author":"Rigatto","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1128\/AAC.02634-15","article-title":"Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B","volume":"60","author":"Rigatto","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1128\/AAC.03064-15","article-title":"Clinical efficacy of polymyxin monotherapy versus nonvalidated polymyxin combination therapy versus validated polymyxin combination therapy in extensively drug-resistant Gram-negative bacillus infections","volume":"60","author":"Cai","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/jcpt.12801","article-title":"Polymyxin B clinical outcomes: A prospective study of patients undergoing intravenous treatment","volume":"44","author":"Mattos","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13756-018-0305-5","article-title":"Efficacy of intravenous plus intrathecal\/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR\/XDR Acinectobacter baumannii: A retrospective cohort study","volume":"7","author":"Pan","year":"2018","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4103\/ijp.ijp_762_20","article-title":"Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections","volume":"55","author":"Simon","year":"2023","journal-title":"Indian J. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13054-023-04522-6","article-title":"Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: The PMB-CROS randomized clinical trial","volume":"27","author":"Liu","year":"2023","journal-title":"Crit. Care"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Garcia, R.C.L., Rodrigues, R.D., Garcia, E.C.L., and Rigatto, M.H. (2023). Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex. Antibiotics, 12.","DOI":"10.3390\/antibiotics12081317"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"772372","DOI":"10.3389\/fmed.2022.772372","article-title":"Polymyxin B\/Tigecycline Combination vs. Polymyxin B or Tigecycline Alone for the Treatment of Hospital-Acquired Pneumonia Caused by Carbapenem-Resistant Enterobacteriaceae or Carbapenem-Resistant Acinetobacter baumannii","volume":"9","author":"Chang","year":"2022","journal-title":"Front. Med."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Zha, L., Zhang, X., Cheng, Y., Xu, Q., Liu, L., Chen, S., Lu, Z., Guo, J., and Tefsen, B. (2023). Intravenous Polymyxin B as Adjunctive Therapy to High-Dose Tigecycline for the Treatment of Nosocomial Pneumonia Due to Carbapenem-Resistant Acinetobacter baumannii and Klebsiella pneumoniae: A Propensity Score-Matched Cohort Study. Antibiotics, 12.","DOI":"10.3390\/antibiotics12020273"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"106880","DOI":"10.1016\/j.ijantimicag.2023.106880","article-title":"Clinical outcomes and safety of intravenous polymyxin B-based treatment in critically ill patients with carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia","volume":"62","author":"Qiao","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/jcpt.13702","article-title":"A retrospective observational study of the treatment with polymyxin B for liver transplantation recipients infected by multidrug-resistant gram-negative bacteria","volume":"47","author":"Yu","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2147\/IDR.S169939","article-title":"Effectiveness and safety of polymyxin B for the treatment of infections caused by extensively drug-resistant Gram-negative bacteria in Thailand","volume":"11","author":"Ngamprasertchai","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11096-018-0766-x","article-title":"Colistin and polymyxin B for treatment of nosocomial infections in intensive care unit patients: Pharmacoeconomic analysis","volume":"41","author":"Quintanilha","year":"2019","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"ofy191","DOI":"10.1093\/ofid\/ofy191","article-title":"The Impact of Acute Kidney Injury on the Risk of Mortality and Health Care Utilization Among Patients Treated with Polymyxins for Severe Gram-Negative Infections","volume":"5","author":"Baradaran","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Wang, J., Shah, B.K., Zhao, J., Xiong, J., Wang, C., and Xie, S. (2023). Comparative study of polymyxin B and colistin sulfate in the treatment of severe comorbid patients infected with CR-GNB. BMC Infect. Dis., 23.","DOI":"10.1186\/s12879-023-08339-0"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jmii.2017.03.007","article-title":"Predictors of polymyxin B treatment failure in Gram-negative healthcare-associated infections among critically ill patients","volume":"51","author":"Ismail","year":"2018","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.diagmicrobio.2007.01.008","article-title":"Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B","volume":"58","author":"Pereira","year":"2007","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e00025-18","DOI":"10.1128\/AAC.00025-18","article-title":"Nephrotoxicity Associated with Intravenous Polymyxin B Once- versus Twice-Daily Dosing Regimen","volume":"62","author":"Okoduwa","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e01617-17","DOI":"10.1128\/AAC.01617-17","article-title":"Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B","volume":"62","author":"John","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.diagmicrobio.2018.11.008","article-title":"Nephrotoxicity prevalence in patients treated with polymyxins: A systematic review with meta-analysis of observational studies","volume":"94","author":"Oliota","year":"2019","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jgar.2022.08.002","article-title":"Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016\u20132018)","volume":"31","author":"Seifert","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1080\/22221751.2021.1948804","article-title":"Novel tigecycline resistance mechanisms in Acinetobacter baumannii mediated by mutations in adeS, rpoB and rrf","volume":"10","author":"Hua","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2165\/11317100-000000000-00000","article-title":"Clinical pharmacokinetics and pharmacodynamics of tigecycline","volume":"48","author":"Barbour","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e01135-17","DOI":"10.1128\/AAC.01135-17","article-title":"Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects","volume":"61","author":"Gotfried","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13613-020-00715-2","article-title":"Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections","volume":"10","author":"Lisi","year":"2020","journal-title":"Ann. Intensive Care"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1089\/mdr.2022.0248","article-title":"Tigecycline-Containing Regimens and Multi Drug-Resistant Acinetobacter baumannii: A Systematic Review and Meta-Analysis","volume":"29","author":"Sodeifian","year":"2023","journal-title":"Microb. Drug Resist."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e17091","DOI":"10.1097\/MD.0000000000017091","article-title":"Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases: A meta-analysis","volume":"98","author":"Gong","year":"2019","journal-title":"Medicine"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Chuang, Y.C., Cheng, C.Y., Sheng, W.H., Sun, H.Y., Wang, J.T., Chen, Y.C., and Chang, S.C. (2014). Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: A matched cohort analysis. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-102"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1248\/bpb.b13-00109","article-title":"Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii","volume":"37","author":"Kwon","year":"2014","journal-title":"Biol. Pharm. Bull."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1007\/s00134-015-4010-z","article-title":"Colistin-tigecycline versus colistin-imipenem-cilastatin combinations for the treatment of Acinetobacter baumannii ventilator-acquired pneumonia: A prognosis study","volume":"41","author":"Chaari","year":"2015","journal-title":"Intensive Care Med."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Kim, W.Y., Moon, J.Y., Huh, J.W., Choi, S.H., Lim, C.M., Koh, Y., Chong, Y.P., and Hong, S.B. (2016). Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0150642"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Ye, J.J., Lin, H.S., Yeh, C.F., Wu, Y.M., Huang, P.Y., Yang, C.C., Huang, C.T., and Lee, M.H. (2016). Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex. BMC Infect. Dis., 16.","DOI":"10.1186\/s12879-016-1717-6"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e12278","DOI":"10.1097\/MD.0000000000012278","article-title":"Treatment outcomes of patients with non-bacteremic pneumonia caused by extensively drug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolates: Is there any benefit of adding tigecycline to aerosolized colistimethate sodium?","volume":"97","author":"Jean","year":"2018","journal-title":"Medicine"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13756-019-0502-x","article-title":"Comparison of Tigecycline or Cefoperazone\/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii","volume":"8","author":"Niu","year":"2019","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Hoban, D.J., Reinert, R.R., Bouchillon, S.K., and Dowzicky, M.J. (2015). Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004\u20132013. Ann. Clin. Microbiol. Antimicrob., 14.","DOI":"10.1186\/s12941-015-0085-1"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e01809-20","DOI":"10.1128\/AAC.01809-20","article-title":"Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN)","volume":"65","author":"Lodise","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Fragkou, P.C., Poulakou, G., Blizou, A., Blizou, M., Rapti, V., Karageorgopoulos, D.E., Koulenti, D., Papadopoulos, A., Matthaiou, D.K., and Tsiodras, S. (2019). The Role of Minocycline in the Treatment of Nosocomial Infections Caused by Multidrug, Extensively Drug and Pandrug Resistant Acinetobacter baumannii: A Systematic Review of Clinical Evidence. Microorganisms, 7.","DOI":"10.3390\/microorganisms7060159"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"S388","DOI":"10.1093\/cid\/ciu594","article-title":"Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: An antimicrobial stewardship approach at the Detroit Medical Center","volume":"59","author":"Pogue","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"S381","DOI":"10.1093\/cid\/ciu593","article-title":"Bad bugs need old drugs: A stewardship program\u2019s evaluation of minocycline for multidrug-resistant Acinetobacter baumannii infections","volume":"59","author":"Goff","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_122","first-page":"185","article-title":"Preliminary Analysis on the Treatment of Ventilator-Associated Pneumonia Caused by Pandrug-Resistant Acinetobacter baumannii","volume":"36","author":"Wang","year":"2014","journal-title":"Zhongguo Yi XueKeXue Yuan Xue Bao"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1128\/AAC.00981-16","article-title":"Correlation of Checkerboard Synergy Testing with Time-Kill Analysis and Clinical Outcomes of Extensively Drug-Resistant Acinetobacter baumannii Respiratory Infections","volume":"60","author":"Bremmer","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/IPC.0b013e31828bbb82","article-title":"Use of Intravenous Minocycline for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) and Resistant Gram-Negati132-135ve Organisms: Experience in a Tertiary Care Hospital","volume":"22","author":"Bishburg","year":"2014","journal-title":"Infect. Dis. Clin. Pract."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ijantimicag.2018.04.006","article-title":"Absence of TetB identifies minocycline-susceptible isolates of Acinetobacter baumannii","volume":"52","author":"Lomovskaya","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jgar.2018.12.001","article-title":"Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: A retrospective matched cohort study","volume":"17","author":"Liron","year":"2019","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1128\/AAC.02435-13","article-title":"Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections","volume":"58","author":"Sirijatuphat","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40121-020-00357-8","article-title":"Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii: A Prospective, Observational Study","volume":"10","author":"Russo","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jgar.2018.11.016","article-title":"Colistin monotherapy versus colistin\/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: A randomised controlled trial","volume":"17","author":"Park","year":"2019","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1017\/S095026881200194X","article-title":"Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"141","author":"Aydemir","year":"2013","journal-title":"Epidemiol. Infect."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cmi.2016.08.004","article-title":"Acute kidney injury during colistin therapy: A prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections","volume":"22","author":"Andini","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/3\/261\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:14:29Z","timestamp":1760105669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/3\/261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":132,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["antibiotics13030261"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13030261","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]}}}